Webcasts

IOTOD hosts a selection of webcasts from the IOTOD conference that you can access for free to improve your knowledge in opioid dependence care, hepatitis C treatment, overdose prevention and much more.

We will be adding more webcasts following the next IOTOD conference, sign up to the newsletter to ensure you don’t miss the next release!

2018

Manoeuvres in the fog: drug-drug interactions in OST

Dr Stephan Walcher

Dr Stephan Walcher focuses on pharmacokinetic and pharmacodynamic drug-drug interactions (DDIs) and their consequences. He discusses DDIs associated with drugs used in the treatment of HIV, HCV and psychiatric disorders as well as strategies for avoiding adverse interactions.

Practicalities of transitioning between opioid agonist treatments

Mr Duncan Hill

Mr Duncan Hill discusses the strategies, guidelines and challenges surrounding transitioning from methadone to buprenorphine and from buprenorphine to methadone.

New horizons for treatment: translating the latest research into clinical practice

Professor Marc Auriacombe

Professor Marc Auriacombe considers the clinical impact of recent developments in opioid dependence treatment options and emerging challenges in Europe.

Tailoring behavioural interventions: emerging evidence and practical implications

Professor John Marsden

Professor John Marsden looks into the ways of tailoring interventions according to history, preference and adjusting by response.

Improving outcomes with psychosocial interventions

Dr Ed Day

Dr Ed Day focuses on the importance of providing psychosocial interventions (PSIs), reviewing the current guidelines and suggesting practical advice for PSIs.

Polydrug use: emerging challenges

Dr José Martínez Raga

Dr José Martínez Raga addresses concurrent substance dependencies in opioid-dependent patients and the emerging challenges this presents.

The current landscape of opioid overdoses and harm-reduction strategies in Europe

Isabelle Giraudon

Isabelle Giraudon provides a comprehensive overview of the current status of opioid overdoses in Europe and the currently available strategies for harm-reduction.

The provision of this video has been supported by an education grant from Mundipharma International Ltd. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run at arm’s length from the financial supporter and all content is created by the faculty or scientific secretariat. The financial supporter has had no involvement in the creation or development of the educational content.

Novelties and nuances in naloxone

Dr Rebecca McDonald

Rebecca McDonald explores pharmacokinetics of differently available naloxone formulation and the different routes of administration available now and in the near future in Europe.

The provision of this video has been supported by an education grant from Mundipharma International Ltd. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run at arm’s length from the financial supporter and all content is created by the faculty or scientific secretariat. The financial supporter has had no involvement in the creation or development of the educational content.

Harm-reduction strategies: reaching marginalised populations

Professor Heino Stöver

Heino Stöver presents on the different harm reduction strategies that can be used to engage marginalised populations (such as homeless people, sex workers, prisoners and many more).

The provision of this video has been supported by an education grant from Mundipharma International Ltd. PCM Scientific is the medical education company acting as scientific secretariat and organiser for this programme. The activity is run at arm’s length from the financial supporter and all content is created by the faculty or scientific secretariat. The financial supporter has had no involvement in the creation or development of the educational content.

Why bother? Building a case for HCV therapy

Professor Graham Foster

Graham Foster instructs the audience on why they should take an interest in treating Hepatitis C in people who use drugs, sooner rather than later.

HCV treatment options

Dr Marc Bourlière

Marc Bourlière takes the audience through the incredible advances in treatment options for Hepatitis C in recent years, and how these advances could bring us closer to the ultimate goal of Hepatitis C elimination.

Optimising the patient pathway

Professor Olav Dalgard

Olav Dalgard discusses the barriers that prevent patients from receiving treatment for their Hepatitis C and how, by minimising the pathway to treatment, more patients can be cured.

Implications of comorbid psychiatric disorders

Dr Carlos Roncero

Dr Carlos Roncero outlines the common psychiatric comorbidities in opioid-dependent patients.

Strategies for treatment-refractory patients

Professor Wim van den Brink

Professor Wim van den Brink discusses heroin-assisted treatment.

Social issues and interventions: spotlight on homelessness

Ms Susan McCutcheon

Susan McCutcheon takes the audience through the challenges faced by homeless opioid users and provides practical tips on how the audience could tackle these issues.

2016

The Time is Now

Mr Charles Gore

Providing a powerful summarisation of the current HCV landscape, Mr Charles Gore opens the workshop with a powerful call to action for addictions clinicians.

New Developments in HCV Treatment

Professor Graham Foster

Looking at the new therapeutics available for treating HCV, Professor Graham Foster provides a dynamic, emphatic summary of contemporary treatments.

Nurse-led Hepatitis Care in Addictions Centres

Dr Ashley Brown

While it is useful to know what treatments are now available, it is also important to consider steps to successful implementation. Here, Dr Ashley Brown shares his team’s model for community-based care.

Patient Journey 1: Initial Diagnosis

Dr Hemant Shah

Join Dr Hemant Shah as we meet James, a model patient who has screened positive for HCV antibodies. In this illustrative case study, Dr Shah demonstrates key communication skills when providing an initial diagnosis of hepatitis C.

Patient Journey 2: Fibrosis Assessment

Dr Hemant Shah

After motivating James to undertake a liver fibrosis assessment, the patient and doctor reconvene to discuss the results and their implications. Alongside a refresher on relevant tests and how to interpret them, Dr Shah and James model common challenges surrounding treatment, and techniques to provide successful solutions.

Reports

Achieving HCV elimination
Hepatitis C Virus (HCV) Complexities and comorbidities in HCV care
View all reports